UTHR

United TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$700.00

+27.4% vs current

Most likely

Base case

45%

Probability

Target price

$590.00

+7.4% vs current

B-

Bear case

25%

Probability

Target price

$470.00

-14.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Post-earnings sentiment is mixed rather than clearly bullish. On May 6, 2026, trusted coverage framed the quarter as an EPS and revenue miss, and one earnings write-up said the stock was roughly flat immediately after the release; by May 7, 2026, the packet anchor had UTHR at $569.18, near the packet's median target, suggesting the market did not treat the quarter as a major break in the story. By T+3, delayed analyst reaction appears mixed and incomplete rather than decisive. With limited broad revision data in the packet and only a small target-price cushion versus the anchor, this should remain a tentative monitoring view where pipeline conviction offsets, but does not erase, earnings-quality and execution concerns.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-05catalystPost-earnings execution reset in Tyvaso franchiseMedium impact

Q1 2026 revenue fell 2% year over year to $781.5 million and diluted EPS fell to $5.82, with Tyvaso DPI up 9% to $330.3 million but Nebulized Tyvaso down 22% to $127.2 million; management said it is focused on returning to sequential quarterly revenue growth, so the next few months are an execution test rather than a new thesis reset [#8-K-2026-05-06] [#10-Q-2026-05-06].

2026-08-31eventNebulized Tyvaso IPF sNDA planned by end of summer 2026High impact

The 10-Q says TETON-1 and TETON-2 were successful, integrated analyses were supportive, and the company plans to submit an sNDA to add IPF to the Nebulized Tyvaso label by the end of summer 2026; timely filing would convert a strong clinical story into a visible regulatory milestone for the core franchise [#10-Q-2026-05-06].

2026-08-31eventRalinepag NDA planned by end of summer 2026High impact

The 10-Q says ADVANCE OUTCOMES met its primary endpoint with a 55% reduction in risk of clinical worsening and that United Therapeutics plans to submit an NDA for ralinepag extended-release tablets by the end of summer 2026, creating a second major cardiopulmonary filing catalyst beyond Tyvaso IPF [#10-Q-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology